KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q1 2025 value amounting to $8.6 million.

  • Xenon Pharmaceuticals' Receivables - Net rose 93829.53% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.6 million, marking a year-over-year increase of 93829.53%. This contributed to the annual value of $1.5 million for FY2024, which is 6807.78% up from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' Receivables - Net stood at $8.6 million, which was up 93829.53% from $1.5 million recorded in Q4 2024.
  • In the past 5 years, Xenon Pharmaceuticals' Receivables - Net registered a high of $8.6 million during Q1 2025, and its lowest value of $805000.0 during Q3 2023.
  • Moreover, its 5-year median value for Receivables - Net was $2.2 million (2023), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Receivables - Net tumbled by 6756.65% in 2023, and later skyrocketed by 93829.53% in 2025.
  • Xenon Pharmaceuticals' Receivables - Net (Quarter) stood at $2.8 million in 2021, then crashed by 64.34% to $986000.0 in 2022, then decreased by 11.36% to $874000.0 in 2023, then surged by 68.08% to $1.5 million in 2024, then skyrocketed by 488.77% to $8.6 million in 2025.
  • Its Receivables - Net stands at $8.6 million for Q1 2025, versus $1.5 million for Q4 2024 and $938000.0 for Q3 2024.